Celldex Therapeutics, Inc. (CLDX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 158.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $158.00K | (m) | (m) |
| 2026-03-31 | (m) | $865.00K | (m) | (m) |
| 2025-12-31 | (m) | $1.54M | $200.00K | (m) |
| 2025-09-30 | (m) | $2.60M | (m) | (m) |
| 2025-06-30 | (m) | $5.79M | (m) | (m) |
| 2025-03-31 | (m) | $7.56M | (m) | (m) |
| 2024-12-31 | (m) | $7.02M | $200.00K | (m) |
| 2024-09-30 | (m) | $9.98M | (m) | (m) |
| 2024-06-30 | (m) | $8.30M | (m) | (m) |
| 2024-03-31 | (m) | $6.07M | (m) | (m) |
| 2023-12-31 | (m) | $6.88M | $300.00K | (m) |
| 2023-09-30 | (m) | $4.37M | (m) | (m) |
| 2023-06-30 | (m) | $3.25M | (m) | (m) |
| 2023-03-31 | (m) | $3.15M | (m) | (m) |
| 2022-12-31 | (m) | $2.36M | $100.00K | (m) |
| 2022-09-30 | (m) | $1.08M | (m) | (m) |
| 2022-06-30 | (m) | $823.00K | (m) | (m) |
| 2022-03-31 | (m) | $4.14M | (m) | (m) |
| 2021-12-31 | (m) | $4.65M | $100.00K | (m) |
| 2021-09-30 | (m) | $8.10M | (m) | (m) |
| 2021-06-30 | (m) | $8.62M | (m) | (m) |
| 2021-03-31 | (m) | $5.38M | (m) | (m) |
| 2020-12-31 | (m) | $7.42M | $200.00K | (m) |
| 2020-09-30 | (m) | $4.52M | (m) | (m) |
| 2020-06-30 | (m) | $4.40M | (m) | (m) |
| 2020-03-31 | (m) | $4.88M | (m) | (m) |
| 2019-12-31 | (m) | $3.57M | $100.00K | (m) |
| 2019-09-30 | (m) | $4.45M | (m) | (m) |
| 2019-06-30 | (m) | $4.84M | (m) | (m) |
| 2019-03-31 | (m) | $6.89M | (m) | (m) |
| 2018-12-31 | (m) | $9.54M | $700.00K | (m) |
| 2018-09-30 | (m) | $11.23M | (m) | (m) |
| 2018-06-30 | (m) | $14.21M | (m) | (m) |
| 2018-03-31 | (m) | $15.28M | (m) | (m) |
| 2017-12-31 | (m) | $12.74M | (m) | (m) |
| 2017-09-30 | (m) | $11.16M | (m) | (m) |
| 2017-06-30 | (m) | $9.46M | (m) | (m) |
| 2017-03-31 | (m) | $7.02M | (m) | (m) |
| 2016-12-31 | (m) | $6.79M | (m) | (m) |
| 2016-09-30 | (m) | $6.70M | (m) | (m) |
| 2016-06-30 | (m) | $5.51M | (m) | (m) |
| 2016-03-31 | (m) | $6.30M | (m) | (m) |
| 2015-12-31 | (m) | $5.48M | (m) | (m) |
| 2015-09-30 | (m) | $5.17M | (m) | (m) |
| 2015-06-30 | (m) | $5.24M | (m) | (m) |
| 2015-03-31 | (m) | $3.66M | (m) | (m) |
| 2014-12-31 | (m) | $3.59M | (m) | (m) |
| 2014-09-30 | (m) | $2.73M | (m) | (m) |
| 2014-06-30 | (m) | $2.61M | (m) | (m) |
| 2014-03-31 | (m) | $2.11M | (m) | (m) |
| 2013-12-31 | (m) | $4.11M | (m) | (m) |
| 2013-09-30 | (m) | $7.14M | (m) | (m) |
| 2013-06-30 | (m) | $9.27M | (m) | (m) |
| 2013-03-31 | (m) | $11.18M | (m) | (m) |
| 2012-12-31 | (m) | $11.20M | (m) | (m) |
| 2012-09-30 | (m) | $9.99M | (m) | (m) |
| 2012-06-30 | (m) | $9.24M | (m) | (m) |
| 2012-03-31 | (m) | $9.18M | (m) | (m) |
| 2011-12-31 | (m) | $9.27M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $46.79M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $15.18M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |